Clinical data | |
---|---|
Pregnancy cat. | ? |
Legal status | ℞-only (US) |
Routes | Oral |
Identifiers | |
CAS number | 76168-82-6 |
ATC code | None |
PubChem | CID 16132338 |
UNII | 0WX9996O2G |
ChEMBL | CHEMBL1095892 |
Chemical data | |
Formula | C106H170ClN21O30 |
Mol. mass | 2254.05 g/mol |
(verify) |
(what is this?)
Ramoplanin (INN) is a glycolipodepsipeptide antibiotic drug derived from strain ATCC 33076 of Actinoplanes.[1]
It exerts its bacteriocidal effect by inhibiting cell wall biosynthesis, acting by inhibiting the transglycosylation step of peptidoglycan synthesis.[2]
Its development has been fast-tracked by the U.S. Food and Drug Administration as a treatment for multiantibiotic-resistant Clostridium difficile infection of the gastrointestinal tract,[3] although it is unstable in the bloodstream and so can be taken only orally against GI tract infections.[4][5][6]